Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | TBXAS1 | P24557 | 14/20 | 0.66 |
| ▸ | PTGIS | Q16647 | 3/20 | 0.54 |
| ▸ | PDE9A | O76083 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940115 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL2934087 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL2941082 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL1897768 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12329914 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL2934089 | 1.00 | TBXA2R (0.76) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL12330337 | 0.94 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL3104210 | 0.94 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL3104201 | 0.94 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 | |
| SCHEMBL16290261 | 0.94 | TBXA2R (0.67) | TBXA2RCYP1A2CYP3A4MEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150111-B1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2016-10-19 | — | — | EP | claimed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | claimed |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | EVOLVA SA (CH) | 2013-10-10 | — | — | US | claimed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | claimed |
| EP-2150111-B1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| WO-2015193630-A1 | TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES | EVOLVA SA (CH) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193630-A1 | TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES | EVOLVA SA (CH) | 2015-12-23 | — | — | WO | disclosed |
| EP-2934513-A2 | TREATMENT OF CARDIOVASCULAR RISK IN DIABETIC PATIENTS | Evolva SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-2150111-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | Evolva SA (CH) | 2010-02-10 | — | — | EP | disclosed |
| EP-2120567-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | Evolva SA (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008089464-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089461-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | P2RY12, P2RY13, P2RY6 | TBXA2R 19/4885CYP1A2 1425/4885CYP3A4 1172/4885 |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 37/4885CYP3A4 199/4885 |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | TBXA2R 48/4885CYP1A2 592/4885CYP3A4 540/4885 |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | PPARD, PPARG, PPARA | TBXA2R 48/4885CYP1A2 592/4885CYP3A4 540/4885 |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | TBXA2R 1/4885CYP1A2 37/4885CYP3A4 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.